Iron deficiency anemia (IDA) is a common complication in non-dialysis chronic kidney disease (ND-CKD) patients, often exacerbated by inflammation and impaired iron utilization. Treatment strategies involve identifying absolute vs. functional iron deficiency using indicators like TSAT and ferritin levels.1 Conventional therapies include oral iron supplements and intravenous (IV) iron, but these come with risks such as iron overload and oxidative stress. Novel therapies include Ferric citrate (FC), which regulates iron absorption and is FDA-approved for ND-CKD patients, Ferric maltol for patients with inflammatory bowel disease, and Ferric pyrophosphate citrate (FPC), which is delivered via dialysate for hemodialysis patients. Liposomal and Sucrosomial iron offer promising results by bypassing the gastrointestinal tract, reducing side effects, and improving hemoglobin levels.2 These emerging therapies provide safer, more effective alternatives for managing IDA in CKD.